

# Madhur Nayan Mdcem

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1198117/publications.pdf>

Version: 2024-02-01

42  
papers

468  
citations

758635

12  
h-index

752256

20  
g-index

42  
all docs

42  
docs citations

42  
times ranked

833  
citing authors

#	ARTICLE	IF	CITATIONS
1	A machine learning approach to predict progression on active surveillance for prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 161.e1-161.e7.	0.8	11
2	Circumcision and Risk of HIV among Males from Ontario, Canada. Journal of Urology, 2022, 207, 424-430.	0.2	5
3	Active surveillance for intermediate-risk prostate cancer. World Journal of Urology, 2022, 40, 79-86.	1.2	4
4	Predicting survival after radical prostatectomy: Variation of machine learning performance by race. Prostate, 2021, 81, 1355-1364.	1.2	2
5	Supply the demand: Assessment of the feasibility of local nonurologists in relieving the burden of chronic indwelling catheters in a low-income country. Canadian Urological Association Journal, 2021, 15, E261-E266.	0.3	0
6	Long-term outcomes after radical or partial nephrectomy for T1a renal cell carcinoma: A population-based study. Canadian Urological Association Journal, 2020, 14, 392-397.	0.3	3
7	Supply the demand: Assessment of the feasibility of local non-urologists in relieving the burden of chronic indwelling catheters in a low-income country. Canadian Urological Association Journal, 2020, , .	0.3	0
8	Diabetes and kidney cancer survival in patients undergoing nephrectomy: A Canadian multi-center, propensity score analysis. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 576.e11-576.e16.	0.8	3
9	The effect of ethnicity on semen analysis and hormones in the infertile patient. Canadian Urological Association Journal, 2019, 14, 31-35.	0.3	8
10	Metformin Use and Kidney Cancer Survival Outcomes. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 275-284.	0.6	6
11	Editorial Comment. Journal of Urology, 2019, 202, 504-505.	0.2	1
12	A New Model to Predict Benign Histology in Residual Retroperitoneal Masses After Chemotherapy in Nonseminoma. European Urology Focus, 2018, 4, 995-1001.	1.6	26
13	Medication use and kidney cancer survival: A population-based study. International Journal of Cancer, 2018, 142, 1776-1785.	2.3	9
14	Applying Radiomics to Predict Pathology of Postchemotherapy Retroperitoneal Nodal Masses in Germ Cell Tumors. JCO Clinical Cancer Informatics, 2018, 2, 1-12.	1.0	21
15	Challenges Interpreting Chemoprevention Studies Using Observational Data. Journal of Clinical Oncology, 2018, 36, 628-629.	0.8	5
16	The use of assisted reproductive technology before male factor infertility evaluation. Translational Andrology and Urology, 2018, 7, 678-685.	0.6	7
17	CUA-AUA International Fellows Program: San Francisco 2018. Canadian Urological Association Journal, 2018, 12, 227-228.	0.3	0
18	Dissecting the Evolving Risk of Relapse over Time in Surveillance for Testicular Cancer. Advances in Urology, 2018, 2018, 1-7.	0.6	4

#	ARTICLE	IF	CITATIONS
19	Uncoupling Diagnosis and Treatment of Incidentally Imaged Renal Masses. JAMA Internal Medicine, 2018, 178, 727.	2.6	1
20	Impact of oral hypoglycemic agents on mortality among diabetic patients with non-muscle-invasive bladder cancer: A population-based analysis. Canadian Urological Association Journal, 2018, 12, 203-10.	0.3	6
21	Statin use and time to progression in men on active surveillance for prostate cancer. Prostate Cancer and Prostatic Diseases, 2018, 21, 509-515.	2.0	7
22	Statin use and kidney cancer survival outcomes: A systematic review and meta-analysis. Cancer Treatment Reviews, 2017, 52, 105-116.	3.4	53
23	Critical appraisal of the application of propensity score methods in the urology literature. BJU International, 2017, 120, 873-880.	1.3	9
24	The Association Between Vasectomy and Prostate Cancer. JAMA Internal Medicine, 2017, 177, 1273.	2.6	31
25	PD53-07 CONDITIONAL RISK OF RELAPSE IN 3,601 PATIENTS MANAGED WITH SURVEILLANCE FOR STAGE I TESTICULAR CANCER. Journal of Urology, 2017, 197, .	0.2	1
26	Medication use and kidney cancer risk: A population-based study. European Journal of Cancer, 2017, 83, 203-210.	1.3	11
27	Reply from Authors re: Peter Albers. Surveillance of Patients with Clinical Stage I Testis Cancer is Safe and Will Remain Unchanged. Eur Urol 2017;71:130-131. European Urology, 2017, 71, 131-132.	0.9	1
28	Diabetes and kidney cancer outcomes: a propensity score analysis. Endocrine, 2017, 55, 470-477.	1.1	8
29	Metformin Use and Kidney Cancer Outcomes in Patients With Diabetes: A Propensity Score Analysis. Clinical Genitourinary Cancer, 2017, 15, 300-305.	0.9	17
30	Conditional Risk of Relapse in Surveillance for Clinical Stage I Testicular Cancer. European Urology, 2017, 71, 120-127.	0.9	54
31	Prostate-specific antigen testing for prostate cancer screening: A national survey of Canadian primary care physicians' opinions and practices. Canadian Urological Association Journal, 2017, 11, 396-403.	0.3	10
32	The value of complementing administrative data with abstracted information on smoking and obesity: A study in kidney cancer. Canadian Urological Association Journal, 2017, 11, 167.	0.3	6
33	The association between institution at orchiectomy and outcomes on active surveillance for clinical stage I germ cell tumours. Canadian Urological Association Journal, 2016, 10, 204.	0.3	10
34	Randomized controlled trials in testicular cancer: A demographic and quality assessment. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 60.e7-60.e13.	0.8	1
35	Medication use and survival in diabetic patients with kidney cancer: A population-based cohort study. Pharmacological Research, 2016, 113, 468-474.	3.1	19
36	Statin use and kidney cancer outcomes: A propensity score analysis. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 487.e1-487.e6.	0.8	16

#	ARTICLE	IF	CITATIONS
37	Vasectomy and risk of prostate cancer: population based matched cohort study. BMJ, The, 2016, 355, i5546.	3.0	18
38	Hematologic Parameters to Predict Small Renal Mass Biopsy Pathology. Clinical Genitourinary Cancer, 2016, 14, 226-230.	0.9	2
39	The initiation of a multidisciplinary bladder cancer clinic and the uptake of neoadjuvant chemotherapy: A time-series analysis. Canadian Urological Association Journal, 2016, 10, 25.	0.3	17
40	MP10-10 OUTCOMES OF PROGRESSION ON SURVEILLANCE FOR CLINICAL STAGE I NONSEMINOMATOUS GERM CELL TUMOURS. Journal of Urology, 2015, 193, .	0.2	1
41	The effect of metformin on cancer-specific survival outcomes in diabetic patients undergoing radical cystectomy for urothelial carcinoma of the bladder. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 386.e7-386.e13.	0.8	31
42	Lymph Node Yield in Primary Retroperitoneal Lymph Node Dissection for Nonseminoma Germ Cell Tumors. Journal of Urology, 2015, 194, 386-391.	0.2	23